# Aptadir Therapeutics: Research, Milano, Italy

> Aptadir Therapeutics: Aptadir Therapeutics is a biotechnology startup based in Milan, focused on developing RNA inhibitor-based therapies for cancer and...

Source: https://millionrounds.com/startup/aptadir-therapeutics (Millionrounds; every figure on the page links to its filing or article)

Italy · [Research startup](https://millionrounds.com/companies)

# Aptadir Therapeutics

Aptadir Therapeutics is a biotechnology startup based in Milan, focused on developing RNA inhibitor-based therapies for cancer and genetic disorders.

Email

Funding reported Last round: Seed

Research Milano, Italy

Follow Aptadir Therapeutics and see its new rounds in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Faptadir-therapeutics)

Company summary

- **Founded:** - not reported
- **Team:** 4 1 to 10 people
- **Funding reported:** 45.5M as listed, currency not stated
- **Last round:** Seed Sept 2024

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Aptadir Therapeutics has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Aptadir Therapeutics

Aptadir Therapeutics is a biotechnology startup based in Milan, focused on developing RNA inhibitor-based therapies for cancer and genetic disorders.

Founded in 2024, the company specializes in RNA therapeutics, particularly targeting aberrant DNA methylation. Its research is rooted in discoveries from prestigious institutions, including Harvard Medical School and the Cancer Science Institute of Singapore. The company's innovative platform utilizes DNMT1-interacting RNAs (DiRs) to inhibit DNA methyltransferase 1, which helps reactivate hypermethylated genes. Aptadir's lead candidate, Aptadir Ce-49, is designed to target Myelodysplastic Neoplasms (MDS) with a precision approach that minimizes toxicity. The company has raised $1.6 million in pre-seed funding to advance its preclinical programs, with plans for clinical trials by the end of 2025.

## What company datasets say Aptadir Therapeutics raised

Funding, as reported

Reported in all **45.5M** in the source's currency

Last round **Seed**

Last round size **1.6M**

Last round date **Sept 2024**

Investors listed **5**

## On a portfolio page

Investors who name them

- [XGEN Venture](https://millionrounds.com/fund/xgen-venture)

Each firm lists Aptadir Therapeutics on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

rare diseases biotechnology research genetic disorders cancer treatment rna therapeutics

Built with from their website

Google Workspace Gmail

- **Sector:** Research
- **Region:** Lombardia

## Research in Italy

Startups like it

- [**Genespire** Milan · founded 2020](https://millionrounds.com/startup/genespire)
- [**Resalis Therapeutics** Turin · founded 2021](https://millionrounds.com/startup/resalis-therapeutics)
- [**Sibylla Biotech** Bresso · founded 2017](https://millionrounds.com/startup/sibylla-biotech)
- [**Algorithmiq** Milano · founded 2020](https://millionrounds.com/startup/algorithmiq)
- [**Phononic Vibes** Milan · founded 2018](https://millionrounds.com/startup/phononic-vibes-2)
- [**Contraria Biotech** Siena · founded 2017](https://millionrounds.com/startup/contraria-biotech)
- [**Cellply** Bologna · founded 2013](https://millionrounds.com/startup/cellply)
- [**Altheia Science** Milan · founded 2017](https://millionrounds.com/startup/altheia-science)

## Is this your company?

Add your raise, your deck and your story, and put Aptadir Therapeutics in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)